Found 10 articles for: "Erythema"
The Role of JAK Inhibitors in the Treatment of Cutaneous Lupus Erythematosus: A Review
December 2024 | Volume 23 | Issue 12 | Original Article | 1100 | Copyright © December 2024
Cutaneous lupus erythematosus (CLE), a manifestation of the chronic autoimmune disease lupus erythematosus (LE), showcases diverse clinical, immunologic, and histologic attributes. CLE can be fur...
Read MoreNarrow-Band Intense Pulsed Light as Treatment for Erythematotelangiectatic Rosacea: A Retrospective Study
November 2023 | Volume 22 | Issue 11 | Original Article | 1095 | Copyright © November 2023
Background: Erythematotelangiectatic rosacea can be successfully treated using various laser and light-based devices. However, the use of narrow-band intense pulsed light for the...
Read MoreTopical Ivermectin Is Associated With Improved Erythematotelangiectatic, Papulopustular, and Phymatous Rosacea in a Secondary Analysis
October 2023 | Volume 22 | Issue 10 | Editorials | 1063 | Copyright © October 2023
Rosacea has variable clinical presentation consisting of four overlapping phenotypes: erythematotelangiectatic, papulopustular, phymatous, and ocular.1 Rosacea's pathogenesis involves incre...
Read MoreReduction of Erythema in Moderate-Severe Rosacea by a Low Molecular Weight Heparan Sulfate Analog (HSA)
June 2023 | Volume 22 | Issue 6 | Original Article | 546 | Copyright © June 2023
Rosacea changes are a result of an immune mediated response and the angiogenic properties of the LL-37 peptide. This peptide induces an inflammatory signal that activates the NLRP3-mediated inflammaso...
Read MoreOpen-Label Phase 2 Pilot Study of Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE)
April 2023 | Volume 22 | Issue 4 | Features | 425 | Copyright © April 2023
Citation: Alsukait S, Learned C, Rosmarin D. Open-label phase 2 pilot study of oral tofacitinib in adult subjects with Discoid Lupus Erythematosus (DLE). J Drugs Dermatol. 2023;22(4)...
Read MoreSuccessful Management of Erythema Dyschromicum Perstans Following Topical Ruxolitinib Therapy
March 2023 | Volume 22 | Issue 3 | Case Reports | 297 | Copyright © March 2023
Erythema dyschromicum perstans (EDP) is a rare cutaneous disorder in which patients develop gray or blue-brown macules or patches on their bodies.1 This condition does not appear to have a ...
Read MoreA Retrospective Study of Calcinosis Cutis in Patients With Systemic Lupus Erythematosus
October 2022 | Volume 21 | Issue 10 | Editorials | 1137 | Copyright © October 2022
Calcinosis cutis (CC) is a very rare and poorly characterized finding in systemic lupus erythematosus (SLE).1 In this retrospective study, we present our experience of 10 individuals with S...
Read MorePlatelet Rich Plasma for the Treatment of Scarring Alopecia Due to Discoid Lupus Erythematosus
March 2022 | Volume 21 | Issue 3 | Case Reports | 309 | Copyright © March 2022
Platelet-rich plasma (PRP) is an autologous concentration of plasma from a patient’s blood containing platelets up to 7 times higher than normal plasma. Originally indicated to improve connectiv...
Read MoreUpdate on Facial Erythema in Rosacea
August 2021 | Volume 20 | Issue 8 | Original Article | 861 | Copyright © August 2021
Dermatologists are cognizant of the multiple clinical manifestations of rosacea, particularly persistent facial erythema, which has been deemed to be the most prevalent diagnostic feature and often po...
Read MoreCharacterization and Clinical Significance of Non-Scarring Alopecia in Systemic Lupus Erythematosus
May 2021 | Volume 20 | Issue 5 | Editorials | 584 | Copyright © May 2021